G1 Therapeutics to Present Positive Clinical and Preclinical Data on CDK4/6 Inhibitor G1T28 at December Scientific Conferences

November 21, 2016 4:38 AM ET

RESEARCH TRIANGLE PARK, NC, November 21, 2016 – G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that preliminary clinical data from its lead CDK4/6 inhibitor G1T28 for patients with small-cell lung cancer (SCLC) will be presented at the International Association for the Study of Lung Cancer’s 17th World Conference on Lung Cancer (WCLC), to be held December 4 – 7 at the Messe Wien Exhibition & Congress Center in Vienna, Austria. Details on the poster are as follows:

Title: G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results
Poster Session: PS01
Poster Number: P1.07-002
Date / Time: Monday, December 5, 2:30 p.m. – 3:45 p.m. CET
Location: Hall B of the Messe Wien Exhibition & Congress Center
Presenter: Lowell L. Hart, M.D., Florida Cancer Specialists, Fort Myers, FL

G1 will also present preclinical data on G1T28 in a poster session at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, to be held November 29 – December 2 at the Internationales Congress Center Munich in Munich, Germany. Details on the poster are as follows:

Title: G1T28, a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy
Poster Session: Molecular targeted agents II
Poster Number: P118
Date / Time: Thursday, December 1, 10:15 a.m. – 5 p.m. CET
Location: The Exhibition Hall of Internationales Congress Center Munich
Presenter: Patrick J. Roberts, Ph.D., Pharm.D., Director of Translational Medicine, G1 Therapeutics

About G1T28
G1T28 is a potential first-in-class, short-acting IV CDK4/6 inhibitor being developed to preserve hematopoietic stem cells and enhance immune system function during chemotherapy. G1T28 is being studied in two Phase 1b/2a proof-of-concept trials in patients with small-cell lung cancer: a study in newly diagnosed, treatment-naive patients (NCT02499770), and a study in previously treated patients (NCT02514447).

About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in people with cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC. Visit www.g1therapeutics.com for more information.

###

Contact:
Mark Velleca, MD, PhD
G1 Therapeutics
919-213-9838
mvelleca@g1therapeutics.com

Media: